- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.05. | Pharma downplays tariff threat, even as risks remains unclear | ||
| 01.05. | CVS strikes Wegovy deal with Novo Nordisk | ||
| 01.05. | Arvinas, Entrada cut staff; Merck builds US hub for Keytruda | ||
| 01.05. | AstraZeneca quietly exits neuroscience | ||
| 01.05. | Madrigal's MASH drug sales again top Wall Street projections | ||
| 01.05. | Siren, a gene therapy startup, tests unconventional alternative to venture funding | ||
| 30.04. | Novartis to acquire Regulus in deal for kidney disease drug | ||
| 30.04. | J&J secures FDA OK for immune drug touted as future blockbuster | ||
| 30.04. | BridgeBio sales of new heart drug outstrip expectations | ||
| 29.04. | Acelyrin should liquidate instead of merging with Alumis, investor says | ||
| 29.04. | Pfizer's Bourla 'cautiously optimistic' on looming US pharma tariffs | ||
| 29.04. | Novo partners with telehealth companies in move to expand Wegovy market | ||
| 29.04. | FDA misses approval deadline for biotech's rare disease drug | ||
| 29.04. | Abeona cell therapy approved by FDA for rare skin condition | ||
| 28.04. | Novavax says vaccine application still 'approvable,' despite FDA delay | ||
| 28.04. | Merck KGaA to buy biotech SpringWorks for $3.9B | ||
| 28.04. | New Akeso, Summit data stir debate on PD-1/VEGF drugs | ||
| 28.04. | Top Republican calls for 340B reform in long-awaited investigation | ||
| 28.04. | How integrated real-world data helps identify and improve outcomes for rare disease patients | ||
| 25.04. | Biohaven stock slides on withdrawal of European marketing application | ||
| 25.04. | Gilead leans on HIV drugs as oncology sales slow | ||
| 25.04. | Halozyme sues Merck; FDA blames cuts for Vanda delay | ||
| 25.04. | Caribou, in reversal, scraps autoimmune cell therapy and cuts staff | ||
| 24.04. | Bristol Myers says schizophrenia drug launch 'off to a solid start' | ||
| 24.04. | Merck takes $200M tariff hit, trimming its gross profits |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .